Clinical Trials · NCT03096847
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 502
- Start date
- Oct 2016
- Locations
- 84 sites, Germany
- Primary endpoint
- Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole